MET mutation
|
NSCLC
|
MET mutation
|
NSCLC
|
Immunotherapy Resistant: C3 – Early Trials
Thorac Cancer - 3 weeks (NewC3)
|
Immunotherapy Resistant: C3 – Early Trials
Thorac Cancer - 3 weeks - (New C3)
|
MET mutation
|
RCC
|
MET mutation
|
RCC
|
savolitinib Sensitive: B - Late Trials
|
savolitinib Sensitive: B - Late Trials
|
MET mutation
|
Gastric Cancer
|
MET mutation
|
Gastric Cancer
|
TPX-0022 Sensitive: C2 – Inclusion Criteria
|
TPX-0022 Sensitive: C2 – Inclusion Criteria
|
MET mutation
|
NSCLC
|
MET mutation
|
NSCLC
|
crizotinib Sensitive: C2 – Inclusion Criteria
|
crizotinib Sensitive: C2 – Inclusion Criteria
|
MET mutation
|
RCC
|
MET mutation
|
RCC
|
cabozantinib capsule Sensitive: C2 – Inclusion Criteria
|
cabozantinib capsule Sensitive: C2 – Inclusion Criteria
|
MET mutation
|
RCC
|
MET mutation
|
RCC
|
crizotinib Sensitive: C2 – Inclusion Criteria
|
crizotinib Sensitive: C2 – Inclusion Criteria
|
MET mutation
|
RCC
|
MET mutation
|
RCC
|
c-MET inhibitor Sensitive: C3 – Early Trials
|
c-MET inhibitor Sensitive: C3 – Early Trials
|
MET mutation
|
RCC
|
MET mutation
|
RCC
|
sunitinib Sensitive: C3 – Early Trials
|
sunitinib Sensitive: C3 – Early Trials
|
MET mutation
|
RCC
|
MET mutation
|
RCC
|
everolimus Sensitive: C3 – Early Trials
|
everolimus Sensitive: C3 – Early Trials
|
MET mutation
|
RCC
|
MET mutation
|
RCC
|
GSK1363089 Sensitive: C3 – Early Trials
|
GSK1363089 Sensitive: C3 – Early Trials
|
MET mutation
|
NSCLC
|
MET mutation
|
NSCLC
|
MTI-31 Sensitive: D – Preclinical
|
MTI-31 Sensitive: D – Preclinical
|